1-(7-Methoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone | 99365-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-(7-Methoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone
• 英文别名: 1-(7-Methoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethanone；1-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
• CAS: 99365-66-9
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: QKOFZEAHFMCOAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  反式-4-甲氧基肉桂酸 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氯化亚砜 、 sodium azide 、 氢气 、 碘 作用下， 以 四氢呋喃 、 乙醇 、 间二甲苯 、 邻二氯苯 、 甲苯 为溶剂， 80.0~120.0 ℃ 、413.69 kPa 条件下， 反应 80.0h， 生成 1-(7-Methoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone
  参考文献：
  名称：

  Ajao, J. F.; Bird, C. W., Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 329 - 331

  摘要：

  DOI：

文献信息

• [EN] 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS<br/>[FR] DERIVES DE 4, 6-DIALKOXY-CINNOLINE SUBSTITUES EN POSITION 4 EN TANT QU'INHIBITEURS DE PHOSPODIESTERASE 10 POUR LE TRAITEMENT DE SYNDROMES PSYCHIATRIQUES OU NEUROLOGIQUES
  申请人：MEMORY PHARM CORP

  公开号：WO2006028957A1

  公开（公告）日：2006-03-16

  The present disclosure relates generally to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by cinnoline compounds of Formulas: (I) and (II); wherein R'-R3 and R15-R18 are as defined herein. Still further, the present invention provides methods for synthesizing compounds with such activity and selectivity, as well as methods of and corresponding pharmaceutical compositions for treating a patient, e.g., mammals, including humans, in need of PDE inhibition. Treatment is preferably for a disease state that involves elevated intracellular PDE10 levels or decreased cAMP and/or cGMP levels, e.g., involving neurological or psychiatric syndromes, especially those states associated with psychoses, most especially schizophrenia or bipolar disorder, obsessive-compulsive disorder, and/or Parkinson’s disease. In particular, such psychoses, obsessive-compulsive disorder, and/or Parkinson’s disease are due at least in part to catabolism of intracellular cAMP and/or cGMP levels by PDE10 enzymes or where such an impaired condition can be improved by increasing cAMP and/or cGMP levels.

  本公开涉及磷酸二酯酶10（PDE10）酶被Formula（I）和（II）的喹啉类化合物抑制；其中R'-R3和R15-R18如本文所定义。此外，本发明提供了合成具有此类活性和选择性的化合物的方法，以及用于治疗需要PDE抑制的患者，例如哺乳动物，包括人类的方法和相应的药物组合物。治疗最好用于涉及细胞内PDE10水平升高或cAMP和/或cGMP水平降低的疾病状态，例如涉及神经系统或精神症候群，尤其是与精神病、强迫症、帕金森病有关的状态。特别是这些精神病、强迫症和/或帕金森病至少部分是由PDE10酶分解细胞内cAMP和/或cGMP水平引起的，或者这种受损状态可以通过增加cAMP和/或cGMP水平来改善。
• Phosphodiesterase 10 inhibitors
  申请人：Arrington Phillip Mark

  公开号：US20070093515A1

  公开（公告）日：2007-04-26

  Provided are certain quinazolines that are PDE10 inhibitors, pharmaceutical compositions, containing the same and processes for preparing the same. Also provided are methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like, by administering those certain quinazolines.

  提供了某些喹唑啉类化合物作为PDE10抑制剂，以及含有这些化合物的药物组合物和制备这些化合物的方法。同时，还提供了通过给予这些喹唑啉类化合物治疗可由PDE10酶治疗的疾病（如肥胖症、非胰岛素依赖性糖尿病、精神分裂症或躁郁症、强迫症等）的方法。
• AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM
  申请人：McKittrick A. Brian

  公开号：US20080089858A1

  公开（公告）日：2008-04-17

  Disclosed are compounds of the formula: and compounds of the formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.

  本发明涉及以下式的化合物：以及以下式的化合物：其中R1，R2，R3，R4，R5，u和v如本文所定义。本发明还涉及使用I或IIA式化合物治疗疼痛（例如，炎性疼痛，慢性疼痛和神经病理性疼痛）的方法，治疗糖尿病的方法以及抑制胆固醇吸收的方法。
• AJAO, J. F.;BIRD, C. W., J. HETEROCYCL. CHEM., 1985, 22, N 2, 329-331
  作者：AJAO, J. F.、BIRD, C. W.

  DOI：——

  日期：——
• SEPIAPTERIN REDUCTASE INHIBITORS
  申请人：QUARTET MEDICINE, INC.

  公开号：US20170096435A1

  公开（公告）日：2017-04-06

  Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.